Is Abbott Laboratories overvalued or undervalued?

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price.
In comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance.